Jpmorgan Chase & CO Tcr2 Therapeutics Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.83 - $1.44 $1,298 - $2,252	-1,564 Reduced 0.3%	524,184 $524,000
Q3 2022 Nov 14, 2022	SELL	$1.86 - $3.75 $323,904 - $653,032	-174,142 Reduced 24.88%	525,748 $947,000
Q2 2022 Aug 11, 2022	SELL	$2.11 - $2.94 $28,955 - $40,345	-13,723 Reduced 1.92%	699,890 $2.03 Million
Q1 2022 May 11, 2022	SELL	$2.4 - $4.71 $521,332 - $1.02 Million	-217,222 Reduced 23.34%	713,613 $1.97 Million
Q4 2021 Feb 10, 2022	SELL	$4.58 - $8.34 $455,824 - $830,038	-99,525 Reduced 9.66%	930,835 $4.34 Million

Q3 2021 Nov 12, 2021	BUY	$8.44 - $18.35 $8.7 Million - $18.9 Million	1,030,360 New	1,030,360 $8.77 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.